Multicentric non-randomized phase II of pembrolizumab in combination with etoposide-cisplatin-based chemotherapy in first-line small cell ovarian carcinoma of hypercalcemic type

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515310-40-01

Acronym

GINECO-OV243b

Enrollment

Registered

2024-10-01

Start date

2021-08-04

Completion date

Unknown

Last updated

2026-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with a confirmed diagnosis of ovarian small cell carcinoma.

Brief summary

Complete response rate is documented using RECIST 1.1

Detailed description

Safety will be assessed using NCI CTC-AE v5, Efficacy will be documented using RECIST 1.1.

Interventions

DRUGEtoposide 20 mg/ml Concentrate for solution for infusion

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

DRUGCisplatine Teva 1 mg/ml solution à diluer pour perfusion.

DRUGADRIBLASTINE 10 mg

DRUGpoudre pour solution injectable en flacon

DRUGCyclophosphamide Sandoz

DRUG100 mg/mL

DRUGkoncentrat do sporządzania roztworu do wstrzykiwań / do infuzji

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Complete response rate is documented using RECIST 1.1	—

Secondary

Measure	Time frame
Safety will be assessed using NCI CTC-AE v5, Efficacy will be documented using RECIST 1.1.	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026